Prashant Kapoor, MD

Articles by Prashant Kapoor, MD

Frontline Quadruplet Therapy in NDMM: GRIFFIN and MASTER Studies

ByShaji Kumar, MD, Mayo Clinic,Morie A. Gertz, MD, MACP, Mayo Clinic,David Dingli, MD, PhD,Prashant Kapoor, MD

May 10th 2022

Expert perspectives on frontline daratumumab-containing quadruplet regimens in the context of recent clinical trials in newly diagnosed multiple myeloma.

Prashant Kapoor, MD

Articles by Prashant Kapoor, MD

Frontline Quadruplet Therapy in NDMM: GRIFFIN and MASTER Studies

Trending on CancerNetwork

FDA OKs Lutetium Lu 177 Vipivotide Tetraxetan in Metastatic Prostate Cancer

Subcutaneous Amivantamab Receives FDA Priority Review in R/M HNSCC

FDA Advisory Committee Backs RP1/Nivolumab for Advanced Melanoma

What Does Practical CAR T Cell Use Look Like in Multiple Myeloma Care?

Sneak Peek: Practical CAR T Cell Use in Multiple Myeloma Care